However, clinical trials uncover the occurrence of several molecular mechanisms that trigger TRAIL resistance in several tumors among which HCC, pointing to the relevance of studies aimed to the identification of combined therapeutic approaches that may overcome this resistance and improve the efficacy of TRAIL-based therapy. The gene discussed is TNFSF10; the disease is hepatocellular carcinoma.